Key result
Preservative-free carteolol reduces intraocular pressure by ~23% once daily with favorable safety.
Why the study?
This paper summarizes and compares the indications, contraindications, adverse effects, and safety profiles of topical beta-blocker ophthalmic drops accessible in Poland for glaucoma therapy.
Does once-daily preservative-free 2% carteolol ophthalmic solution improve intraocular pressure control, ocular surface tolerability, and systemic safety compared to 0.5% timolol and 0.5% betaxolol in patients with open-angle glaucoma?
Does once-daily preservative-free 2% carteolol ophthalmic solution improve intraocular pressure control, ocular surface tolerability, and systemic safety compared to 0.5% timolol and 0.5% betaxolol in patients with open-angle glaucoma?
Preservative-free, prolonged-action 2% carteolol once daily offers comparable intraocular pressure reduction (20–25%) to timolol with fewer cardiovascular, metabolic, and ocular surface adverse effects due to its intrinsic sympathomimetic activity and lack of benzalkonium chloride.
Answers are grounded in this paper and cite their sources.
Supports potential first-line role in open-angle glaucoma; leaves open need for head-to-head randomized trials.
Topical β-blockers, both selective and non-selective, are first-line therapeutic options in different types of glaucoma, particularly in its most common type – open angle glaucoma. In this paper the author is summarizing and comparing characteristics of β-blocker ophthalmic drops accessible in Poland: carteolol, betaxolol and timolol, describing indications and contraindications for their use in glaucoma therapy, possible adverse effects and general safety profile. Preservative free 2% carteolol ophthalmic solution, compared to other topical β-blokers, indicates that it may be a valuable alternative in first choice glaucoma therapy, thanks to some properties, which distinguish the drug within the group. It’s sufficient hypotensive effect enables 2% carteolol to be used it in glaucoma monotherapy, the unique intrinsic sympathomimetic activity allows safer application in patients with some concomitant systemic diseases and once-daily long acting preservative free formula simplifies dosing, improves patient’s adherence and persistence in and increases therapy comfort, minimizing adverse effects on ocular surface.
No takes yet. Share an insight, caveat, or question.
J Wasyluk (2026) conducted a review in Open-angle glaucoma. Preservative-free 2% carteolol ophthalmic solution vs. Other topical beta-blockers (0.5% timolol twice daily and 0.5% betaxolol twice daily) was evaluated on Intraocular pressure (IOP) reduction. Preservative-free 2% carteolol reduces intraocular pressure by 20–25% with once-daily dosing while intrinsic sympathomimetic activity and lack of preservatives improve systemic and ocular safety.
Synapse has enriched 10 related papers. Consider them for comparative context: